Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown. METHODS: We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI). RESULTS: Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups. CONCLUSIONS: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although effective, ERT is limited by an approximately 40% noncompliance rate, costs ≥$200,000 annually, and advances arthropathy.172, 173, 174, 175”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [172]
Citations
Cites
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
A Radiologic Classification of Hemophilic Arthropathy
PETTERSSON, H., AHLBERG, Å., & NILSSON, I. M. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198006000-00018 · Cited by 549
Proceedings: A more uniform measurement of factor VIII inhibitors.
Ck, K., Aledort, L. M., Aronson, D. D., Counts, R., Edson, van Eys, J., Fratantoni, J. C., Green, D., Hampton, J., Hilgartner, M. W., et al. (1975) · PubMed · Cited by 346
Barriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationAhlberg, Å. (1965) · Acta Orthopaedica Scandinavica · doi:10.3109/ort.1965.36.suppl-77.01 · Cited by 252
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
Soucie, J. M. (2004) · Blood · doi:10.1182/blood-2003-05-1457 · Cited by 244
Self-citationIorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
Nuss, R., Kilcoyne, R. F., Geraghty, S., Shroyer, A. L. W., Rosky, J. W., Mawhinney, S., Wiedel, J., & Manco‐Johnson, M. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00383.x · Cited by 159
Self-citationLee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., Kreuz, W., Escuriola‐Ettingshausen, C., Funk, M. J., SCHMIDT, H., & Kornhuber, B. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440413.x · Cited by 154
Research works printed but not linked: 5
- Robinson PM, 1967, Can Med Assoc J, 97, 559
- Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #193. New York: National Hemophilia Foundation, March 11, 1994.
- Stobart K, 2006, Cochrane Database Syst Rev, 2, CD003429
- Kasper CK, 1975, Thromb Diath Haemorr, 34, 612
- Report on the Universal Data Collection Program. Atlanta: Centers for Disease Control and Prevention, 2005;7(1):28. (Accessed July 18, 2007, athttp://www.cdc.gov/ncbddd/hbd/documents/UDC7%281%29.pdf.)
Cited by
Items 101–200 of 1,000
Feola, G., Molinari, A. C., Santoro, C., Rivolta, G. F., Cultrera, D., Gagliano, F., Zanon, E., Mancuso, M. E., Valdré, L., Mameli, L., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-05-0407 · Cited by 114
“Two randomised trials (4, 5) have conclusively shown that preventing bleeding from an early age with primary prophylaxis (started before age three years or before two joint bleeds have occurred [6]) or early secondary prophylaxis (started later in childhood [6]) can preserve joint function, avoiding or greatly reducing”
BackgroundSelf-citationHemophilia and inhibitors: current treatment options and potential new therapeutic approaches
Meeks, S. L., & Batsuli, G. M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.657 · Cited by 116
“Despite these limitations, patients with inhibitors often benefit from prophylaxis therapy with BPAs pending the start of ITI, during ITI, and indefinitely if ITI fails for prevention of recurrent joint bleeds, hemophilic arthropathy, and subsequent disability.(22,23) Prospective studies of both aPCC (85 U/kg on 3 non…”
BackgroundThe burden of bleeding in haemophilia: is one bleed too many?
Gringeri, A., Ewenstein, B. M., & Reininger, A. J. (2014) · Haemophilia · doi:10.1111/hae.12375 · Cited by 110
Aspects of current management: orthopaedic surgery in haemophilia
RODRIGUEZ‐MERCHAN, E. C. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02544.x · Cited by 110
Co‐morbidities and quality of life in elderly persons with haemophilia
Franchini, M., & Mannucci, P. M. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08005.x · Cited by 110
2017 Clinical trials update: Innovations in hemophilia therapy
Hartmann, J., & Croteau, S. E. (2016) · American Journal of Hematology · doi:10.1002/ajh.24543 · Cited by 118
Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates
Mancuso, M. E., & Santagostino, E. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6040039 · Cited by 112
“In the frame of this favorable scenario, the optimal form of replacement therapy is long-term regular prophylaxis since childhood, which is able to overthrow bleeding frequency particularly into joints, therefore reducing the development of chronic arthropathy [5,6].”
BackgroundWu, R., Luke, K. H., Poon, M. ‐., WU, X., Zhang, N., Zhao, L., Su, Y., & Zhang, J. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02348.x · Cited by 105
Pipe, S. W. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-10-0593 · Cited by 118
“In the recently published Joint Outcome Study, the estimated annual cost for prophylactic treatment of one patient with recombinant rFVIII was $300,000 USD (86).”
BackgroundAdvances and challenges for hemophilia gene therapy
Batty, P. A., & Lillicrap, D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz157 · Cited by 114
“The aim of prophylaxis is to raise FVIII or FIX activity above a level that is detectable (>1%) to prevent bleeding and reduce or delay the incidence of joint disease (2,3).”
BackgroundDiagnosis and management of haemophilia
Fijnvandraat, K., Cnossen, M. H., Leebeek, F. W. G., & Peters, M. (2012) · BMJ · doi:10.1136/bmj.e2707 · Cited by 111
WFH: Closing the global gap – achieving optimal care
Skinner, M. W. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02822.x · Cited by 106
Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis
Bannow, B. S., Recht, M., Négrier, C., Hermans, C. R. J. R., Berntorp, E. E., Eichler, H., Mancuso, M. E., Klamroth, R., O’Hara, J., Santagostino, E., et al. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.03.002 · Cited by 108
“The Joint Outcomes Study demonstrated that children treated with FVIII primary prophylaxis had less joint damage and were more likely to remain free from joint damage as compared with peers treated ondemand [17].”
BackgroundSelf-citationVascular remodeling underlies rebleeding in hemophilic arthropathy
Bhat, V., Olmer, M., Joshi, S., Durden, D. L., Cramer, T. J., Barnes, R. F. W., Ball, S. T., Hughes, T. H., Silva, M., Luck, J. V., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24133 · Cited by 107
“However, the reasons for continued progression of joint disease remain unknown, and may be associated with perpetuated clinical but also subclinical bleeding irrespective of clotting factor replacement [11,19].”
BackgroundMurakami, M., Okuyama, Y., Ogura, H., Asano, S., Arima, Y., Tsuruoka, M., Harada, M., Kanamoto, M., Sawa, Y., Iwakura, Y., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100900 · Cited by 100
“It is known that microbleeding, which occurs even in the joints of healthy individuals, can trigger hemarthrosis in hemophilia patients because of defects in blood coagulation (Aledort et al., 1994; Manco-Johnson et al., 2007; Hakobyan et al., 2008).”
Factor VIII replacement is still the standard of care in haemophilia A.
Aledort, L. M., Mannucci, P. M., Schramm, W., & Tarantino, M. D. (2019) · Blood transfusion · doi:10.2450/2019.0211-19 · Cited by 100
US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors
Valentino, L. A., Kempton, C. L., Kruse‐Jarres, R., Mathew, P., Meeks, S. L., Reiss, U. M., & the International Immune Tolerance Induction Study Investigators (2015) · Haemophilia · doi:10.1111/hae.12730 · Cited by 101
Self-citationHemophilia treatment innovation: 50 years of progress and more to come
Mannucci, P. M. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.12.029 · Cited by 110
Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective
Fischer, K., Poonnoose, P. M., Dunn, A. L., Babyn, P., Manco‐Johnson, M. J., David, J. A., van der Net, J. J., Feldman, B. M., Berger, K., Carcao, M. D., et al. (2016) · Haemophilia · doi:10.1111/hae.13088 · Cited by 99
Self-citationGene therapy for hemophilia: what does the future hold?
Doshi, B. S., & Arruda, V. R. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718791933 · Cited by 97
HAKOBYAN, N., ENOCKSON, C., COLE, A. A., SUMNER, D. R., & VALENTINO, L. A. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01689.x · Cited by 97
Self-citationNapolitano, M., Giansily‐Blaizot, M., Dolce, A., Schved, J., Auerswald, G., INGERSLEV, J., Bjerre, J., Altisent, C., Charoenkwan, P., Michaels, L. A., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.074039 · Cited by 96
“A recent, seminal study performed in young children with hemophilia confirmed the superiority of long-term prophylaxis in the prevention of chronic arthropathy, in comparison with on-demand treatment.(8) These results were confirmed by a randomized Italian study.”
MethodResultMuto, A., Yoshihashi, K., Takeda, M., Kitazawa, T., Soeda, T., Igawa, T., Sampei, Z., Kuramochi, T., Sakamoto, A., Haraya, K., et al. (2014) · Blood · doi:10.1182/blood-2014-07-585737 · Cited by 107
“Although traditional on-demand treatment by a FVIII agent cannot prevent hemophilic arthropathy, routine prophylaxis with FVIII to maintain $1% FVIII:C is beneficial in preventing it.(4,5) However, the need for frequent IV injections of FVIII negatively affects patients’ quality of life and their adherence to the rout…”
Barriers and perceived limitations to early treatment of hemophilia
Saxena (2013) · Journal of Blood Medicine · doi:10.2147/jbm.s43734 · Cited by 96
Rentz, A. M., Flood, E. M., Altisent, C., Bullinger, M., Klamroth, R., GARRIDO, R. P., Scharrer, I., Schramm, W., & Gorina, E. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01812.x · Cited by 102
Khawaji, M., Astermark, J., & Berntorp, E. E. (2012) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2012.01750.x · Cited by 95
AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects
Hasbrouck, N. C., & High, K. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.71 · Cited by 100
Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A
Lacroix‐Desmazes, S., Navarrete, A., André, S., Bayry, J., Kaveri, S. V., & Dasgupta, S. (2008) · Blood · doi:10.1182/blood-2008-02-124941 · Cited by 95
Hoots, W. K., Ebbesen, L. S., Konkle, B. A., Auerswald, G., Roberts, H. R., Weatherall, J., Ferran, J.-M., Ljung, R. C. R., & THE NOVOSEVEN (F7HAEM‐1505) INVESTIGATORS (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01654.x · Cited by 94
Self-citationSingh, V., Gohil, N., Ramirez-Garcia, R., Braddick, D., & Fofié, C. K. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26165 · Cited by 96
“, 2010], hemophilia [Manco-Johnson et al., 2007], Duchenne muscular dystrophy [Long et al.”
BackgroundBiss, T. T., Chan, A. K. C., Blanchette, V. S., IWENOFU, L. N., McLimont, M., & Carcao, M. D. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01810.x · Cited by 92
Coppola, A., Minno, M. N. D. D., & Santagostino, E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08263.x · Cited by 90
Doria, A. S. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02307.x · Cited by 90
Validation of a composite score for clinical severity of hemophilia
Schulman, S., Eelde, A., Holmström, M., STÅHLBERG, G., Odeberg, J., & Blombäck, M. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03001.x · Cited by 95
Verma, S., Dutta, T., Mahadevan, S., Nalini, P., Basu, D., Biswal, N., Ramesh, A., Charles, D., Vinod, K. V., & Kumar, K. (2016) · Haemophilia · doi:10.1111/hae.12838 · Cited by 90
Understanding AAV vector immunogenicity: from particle to patient
Dhungel, B. P., Winburn, I. C., Pereira, C. D. F., Huang, K., Chhabra, A., & Rasko, J. E. J. (2024) · Theranostics · doi:10.7150/thno.89380 · Cited by 101
Factor VIII-von Willebrand Factor Complex Inhibits Osteoclastogenesis and Controls Cell Survival
Baud’huin, M., Duplomb, L., Télétchéa, S., Charrier, C., Maillasson, M., Fouassier, M., & Heymann, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.030312 · Cited by 100
Collins, P. W. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02838.x · Cited by 89
Casademunt, E., Martinelle, K., Jernberg, M., Winge, S., Tiemeyer, M., Biesert, L., Knaub, S., Walter, O., & Schröder, C. (2012) · European Journal of Haematology · doi:10.1111/j.1600-0609.2012.01804.x · Cited by 88
“Factor VIII replacement, either on-demand or as prophylaxis, is the mainstay of current therapy for severe disease (defined as FVIII:C <1%); prophylactic treatment has been shown to reduce the number of bleeding episodes and the risk of permanent joint damage (3).”
BackgroundPain and pain management in haemophilia
Auerswald, G., Dolan, G., Duffy, A., Hermans, C. R. J. R., Jiménez‐Yuste, V., Ljung, R. C. R., Morfini, M., Lambert, T., & Šalek, S. Z. (2016) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000571 · Cited by 94
Advances in the treatment of bleeding disorders
Peyvandi, F., Garagiola, I., & Biguzzi, E. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13491 · Cited by 90
Rayment, R., Chalmers, E. A., Forsyth, K., Gooding, R., Kelly, A. M., Shapiro, S., Talks, K., Tunstall, O., Biss, T. T., & British Society for Haematology (2020) · British Journal of Haematology · doi:10.1111/bjh.16704 · Cited by 94
“Commences in early childhood at the latest before the second joint bleed or the age of 3 years, in the absence of documented joint disease, with the aim that the child reaches maturity with normal joints.(3,4)”
BackgroundResultInfluentialKraft, J. K., Blanchette, V. S., Babyn, P., Feldman, B. M., Cloutier, S., Israels, S. J., Pai, M., Rivard, G., Gomer, S., McLimont, M., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12025 · Cited by 87
Half‐life extended factor VIII for the treatment of hemophilia A
Tiede, A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12929 · Cited by 87
The National Center on Birth Defects and Developmental Disabilities
Boyle, C. A., Cordero, J. F., & Trevathan, E. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2012.08.015 · Cited by 86
Kavakli, K., Yang, R., Rusen, L., Beckmann, H., Tseneklidou‐Stoeter, D., Enriquez, M. M., Yang, R., Zhao, Y., Sun, J., Wang, X., et al. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12828 · Cited by 87
Mullins, E. S., Stasyshyn, O., Alvarez‐Román, M. T., Osman, D., Liesner, R. J., Engl, W., Sharkhawy, M., & Abbuehl, B. E. (2016) · Haemophilia · doi:10.1111/hae.13119 · Cited by 94
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement
Iorio, A., Iserman, E. C., Blanchette, V. S., Dolan, G., Ettingshausen, C. E., Hermans, C. R. J. R., Négrier, C., Oldenburg, J., Reininger, A. J., Rodríguez-Merchán, C. E., et al. (2017) · Haemophilia · doi:10.1111/hae.13215 · Cited by 86
Self-citationvan Vulpen, L. F. D., Schutgens, R. E. G., Coeleveld, K., Alsema, E. C., Roosendaal, G., Mastbergen, S. C., & Lafeber, F. P. J. G. (2015) · Blood · doi:10.1182/blood-2015-03-635524 · Cited by 90
Prophylaxis in haemophilia should be life-long.
Makris, M. (2012) · Europe PMC (PubMed Central) · doi:10.2450/2012.0147-11 · Cited by 85
Gene therapy in hemophilia A: a cost-effectiveness analysis
Machin, N., Ragni, M. V., & Smith, K. J. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018021345 · Cited by 87
New therapies using nonfactor products for patients with hemophilia and inhibitors
Nogami, K., & Shima, M. (2018) · Blood · doi:10.1182/blood-2018-07-820712 · Cited by 84
The Aging Patient with Hemophilia: Complications, Comorbidities, and Management Issues
Philipp, C. S. (2010) · Hematology · doi:10.1182/asheducation-2010.1.191 · Cited by 84
Kulkarni, R., Presley, R. J., Lusher, J. M., Shapiro, A. D., Gill, J. C., Manco‐Johnson, M., Koerper, M. A., Abshire, T. C., DiMichele, D., Hoots, W. K., et al. (2016) · Haemophilia · doi:10.1111/hae.13081 · Cited by 84
“In the joint outcome study [10], three young children who suffered life-threatening haemorrhages were all in the on-demand.”
BackgroundSelf-citationAmino acid metabolism as drug target in autoimmune diseases
Mondanelli, G., Iacono, A., Carvalho, A., Orabona, C., Volpi, C., Pallotta, M. T., Matino, D., Esposito, S., & Grohmann, U. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.02.004 · Cited by 84
Quality of life in haemophilia A: Hemophilia Utilization Group Study Va (HUGS‐Va)
Poon, J. L., Zhou, Z., Doctor, J. N., Wu, J., Ullman, M. M., Ross, C. N., Riske, B., Parish, K. L., LOU, M., Koerper, M. A., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02791.x · Cited by 89
Self-citationAthletic Participation in Severe Hemophilia: Bleeding and Joint Outcomes in Children on Prophylaxis
Ross, C. N., Goldenberg, N. A., Hund, D., & Manco‐Johnson, M. J. (2009) · PEDIATRICS · doi:10.1542/peds.2009-0072 · Cited by 86
“Basketball (28) Circuit weight training (7) Baseball (5) Cross country skiing (2) Bowling (2) Cycling (46)b Flag football (3) Frisbee golf (12) Football (American) (14)a Golf (17)”
BackgroundSelf-citationKrishnan, S., Vietri, J., Furlan, R., & Duncan, N. (2014) · Haemophilia · doi:10.1111/hae.12533 · Cited by 82
Yoneyama, K., Schmitt, C., Kotani, N., Levy, G. G., Kasai, R., Iida, S., Shima, M., & Kawanishi, T. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0616-3 · Cited by 85
Optimising prophylaxis in haemophilia A: The ups and downs of treatment
Berntorp, E. E., Hermans, C. R. J. R., Solms, A., Poulsen, L. H., & Mancuso, M. E. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100852 · Cited by 80
Chowdary, P., Carcao, M. D., Kenet, G., & Pipe, S. W. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02139-1 · Cited by 113
Pathophysiology, diagnosis and prevention of arthropathy in patients with haemophilia
Dunn, A. L. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02472.x · Cited by 80
Olivieri, M., Kurnik, K., Pfluger, T., & Bidlingmaier, C. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02682.x · Cited by 80
Social/economic costs and quality of life in patients with haemophilia in Europe
Cavazza, M., Kodra, Y., Armeni, P., Santis, M. D., López‐Bastida, J., Linertová, R., Oliva, J., Serrano‐Aguilar, P., de la Paz, M. P., Taruscio, D., et al. (2016) · The European Journal of Health Economics · doi:10.1007/s10198-016-0785-2 · Cited by 81
Extended Half-Life Factor VIII and Factor IX Preparations
Graf, L. (2018) · Transfusion Medicine and Hemotherapy · doi:10.1159/000488060 · Cited by 79
Sen, D., Chapla, A., Walter, N. M., Daniel, V., Srivastava, A., & Jayandharan, G. R. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12101 · Cited by 88
Risebrough, N. A., Oh, P. I., Blanchette, V. S., Curtin, J. A., Hitzler, J. K., & Feldman, B. M. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01664.x · Cited by 79
Andersson, N. G., Auerswald, G., Barnes, C. D., Carcao, M. D., Dunn, A. L., Fijnvandraat, K., Hoffmann, M. H., Kavaklı, K., Kenet, G., Kobelt, R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14844 · Cited by 85
Self-citationFirst 20 years with recombinant FVIIa (NovoSeven)
Hedner, U. K. E., & Lee, C. A. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02352.x · Cited by 78
The role of ultrasonography in the diagnosis of the musculo‐skeletal problems of haemophilia
Querol, F., & Rodriguez-Merchan, E. C. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02680.x · Cited by 78
Batsuli, G. M., Zimowski, K. L., Tickle, K., Meeks, S. L., & Sidonio, R. F. (2019) · Haemophilia · doi:10.1111/hae.13819 · Cited by 77
European retrospective study of real‐life haemophilia treatment
Berntorp, E., Dolan, G., Hay, C., Linari, S., Santagostino, E., Tosetto, A., Castaman, G., Álvarez‐Román, M., Parra Lopez, R., Oldenburg, J., et al. (2017) · Haemophilia · doi:10.1111/hae.13111 · Cited by 77
Prophylaxis in the haemophilia population
Blanchette, V. S. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02318.x · Cited by 76
How to discuss gene therapy for haemophilia? A patient and physician perspective
Miesbach, W., O’Mahony, B., Key, N. S., & Makris, M. (2019) · Haemophilia · doi:10.1111/hae.13769 · Cited by 113
Rezende, S. M., Neumann, I., Angchaisuksiri, P., Awodu, O. A., Boban, A., Cuker, A. C., Curtin, J. A., Fijnvandraat, K., Gouw, S. C., Gualtierotti, R., et al. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.05.026 · Cited by 96
Nolan, B., Mahlangu, J. N., Perry, D. J., Young, G. A., Liesner, R. J., Konkle, B. A., Rangarajan, S., Brown, S. A., Hanabusa, H., Pasi, J., et al. (2015) · Haemophilia · doi:10.1111/hae.12766 · Cited by 83
Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia
Bladen, M., Main, E., Hubert, N., Koutoumanou, E., Liesner, R. J., & Khair, K. (2013) · Haemophilia · doi:10.1111/hae.12108 · Cited by 75
Duncan, N., Shapiro, A. D., Ye, X., Epstein, J., & LUO, M. P. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02813.x · Cited by 80
Self-citationMinno, M. N. D. D., Iervolino, S., Soscia, E., Tosetto, A., Coppola, A., Schiavulli, M., Marrone, E., Ruosi, C., Salvatore, M., & Minno, G. D. (2013) · Haemophilia · doi:10.1111/hae.12107 · Cited by 75
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia
Thorat, T., Neumann, P. J., & Chambers, J. D. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.7.632 · Cited by 84
Surgery and inhibitor development in hemophilia A: a systematic review
Eckhardt, C. L., van der Bom, J. G., van der Naald, M., Peters, M., Kamphuisen, P. W., & Fijnvandraat, K. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04467.x · Cited by 74
Orthopaedic management of haemophilia arthropathy of the ankle
Pasta, G., Forsyth, A. L., MERCHAN, C. R., Mortazavi, S. M. J., Silva, M., Mulder, K., Mancuso, M. E., Perfetto, O. S., Heim, M., Caviglia, H. A., et al. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01720.x · Cited by 74
Haemophilia care then, now and in the future
Oldenburg, J., Dolan, G., & Lemm, G. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01946.x · Cited by 74
Power Doppler sonography in the diagnosis of hemophilic synovitis – a promising tool
Acharya, S., Schloss, R. W., Dyke, J. P., Mintz, D. N., Christos, P. J., DiMichele, D., & Adler, R. S. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03160.x · Cited by 74
Self-citationMuthard, R. W., & Diamond, S. L. (2013) · Lab on a Chip · doi:10.1039/c3lc41332b · Cited by 73
Arthropathy in Patients with Moderate Hemophilia A: A Systematic Review of the Literature
Franchini, M., Coppola, A., Minno, G. D., Minno, M. N. D. D., & Ambrosino, P. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0033-1354422 · Cited by 76
Nichols, T. C., Dillow, A. M., Franck, H. W. G., Merricks, E. P., Raymer, R. A., Bellinger, D. A., Arruda, V. R., & High, K. A. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.144 · Cited by 73
Recent Advances in the Treatment of Hemophilia: A Review
Marchesini, E., Morfini, M., & Valentino, L. A. (2021) · Biologics · doi:10.2147/btt.s252580 · Cited by 85
Self-citationConsensus Review of the Treatment of Cardiovascular Disease in People With Hemophilia A and B
Ferraris, V. A., Boral, L. I., Cohen, A. J., Smyth, S. S., & White, G. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000045 · Cited by 78
“Familiarity with the general management of hemophilia, par- ticularly the options for treatment or prevention of bleeding, is an essential starting point for understanding the particular aspects of treating PwH who also have cvD. replacement of the deficient factor using specific factor concentrates is a mainstay of t…”
BackgroundInfluentialSelf-citationTreatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study
Scott, M. J., Xiang, H., Hart, D. P., Palmer, B., Collins, P. W., Stephensen, D., Sima, C. S., & Hay, C. R. M. (2018) · Haemophilia · doi:10.1111/hae.13616 · Cited by 74
Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura
Tarasco, E., Bütikofer, L., Friedman, K. D., George, J. N., Hrachovinová, I., Knöbl, P., Matsumoto, M., von Krogh, A. S., Aebi-Huber, I., Čermáková, Z., et al. (2021) · Blood · doi:10.1182/blood.2020009801 · Cited by 77
Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG )
Feldman, B. M., Funk, S. M., Lundin, B., Doria, A. S., Ljung, R. C. R., & Blanchette, V. S. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01750.x · Cited by 71
Self-citationGu, J., Ramsey, P., Evans, V., Tang, L., Apeler, H., Leong, L., Murphy, J. E., Laux, V., & Myles, T. (2014) · Haemophilia · doi:10.1111/hae.12374 · Cited by 70
Prophylaxis in people with haemophilia
Franchini, M., Tagliaferri, A., & Coppola, A. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-07-0483 · Cited by 70
“Manco-Johnson, 2007 [30] Prospective, randomised 65 HA (57 evaluable)° 1.”
la Corte‐Rodríguez, H. D., Rodriguez-Merchan, E. C., Román, M. T. Á., Martín‐Salces, M., Martinoli, C., & Jiménez‐Yuste, V. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1435269 · Cited by 70
Considerations in individualizing prophylaxis in patients with haemophilia A
Valentino, L. A. (2014) · Haemophilia · doi:10.1111/hae.12438 · Cited by 69
“Results from the US Joint Outcome Study Continuation in children and teenagers treated with primary or secondary prophylaxis (NCT01000844) and emerging data from the SPINART trial that compared secondary and tertiary prophylaxis with ondemand therapy in males up to 50 years of age [7] may provide some elucidation.”
BackgroundInfluentialSelf-citationChanging paradigm of prophylaxis with longer acting factor concentrates
Carcao, M. D. (2014) · Haemophilia · doi:10.1111/hae.12405 · Cited by 70
Hemophilia Care in the Pediatric Age
Bertamino, M., Riccardi, F., Banov, L., Svahn, J., & Molinari, A. C. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6050054 · Cited by 69
“in a large cohort prospective study demonstrated the efficacy of prophylaxis with recombinant factor VIII in reducing the incidence of joint hemorrhages, life-threatening hemorrhages, and other hemorrhages and in lowering the risk of joint damage among young boys with severe factor VIII deficiency [32].”
BackgroundThe future of bypassing agents for hemophilia with inhibitors in the era of novel agents
Shapiro, A. D., Mitchell, I. S., & Nasr, S. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14296 · Cited by 69
Self-citationRocino, A., Coppola, A., Franchini, M., Castaman, G., Santoro, C., Zanon, E., Santagostino, E., & Morfini, M. (2014) · Europe PMC (PubMed Central) · doi:10.2450/2014.0223-14 · Cited by 69
Metadata
- Authors
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G. A., Thompson, A. A., McRedmond, K., Soucie, J. M., Austin, H., & Evatt, B. L.
- Affiliations
- University of Colorado Denver (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 535-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167801052
- Cited by
- 1,950
- References
- 27
- Citations by year
- 2026: 57 · 2025: 70 · 2024: 98 · 2023: 115 · 2022: 106 · 2021: 123 · 2020: 127 · 2019: 110 · 2018: 114 · 2017: 107 · 2016: 123 · 2015: 116 · 2014: 131 · 2013: 116 · 2012: 112
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (U27/CCU812106, R00069)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hemophilia A, severe hemophilia, prophylaxis, episodic treatment, recombinant factor VIII, joint destruction, factor VIII inhibitors, joint hemorrhage, children, central venous catheter complications
- MeSH terms
- Child, Child, Preschool, Drug Administration Schedule, Factor VIII, Follow-Up Studies, Hemarthrosis, Hemophilia A, Hemorrhage, Humans, Infant, Infusions, Intravenous, Joint Diseases, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.